Physician profile
Edward M Kramer
NPI 1548302243
$7,196.89
in general payments reported to CMS, 2019-2025
29 companies · $950 in 2025
The $950 reported for 2025 was more than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $641 · 2020: $538 · 2021: $1,435 · 2022: $1,087 · 2023: $1,003 · 2024: $1,543 · 2025: $950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,396 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,395.85 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,708.68 | 2019-2025 | |
| Incyte Corporation | $888.35 | 2021-2025 | Opzelura |
| Pfizer INC. | $759.29 | 2019-2025 | |
| Ucb, INC. | $631.11 | 2023-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $627.33 | 2019-2025 | Winlevi, Absorica Ld |
| Janssen Biotech, INC. | $564.54 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Merz North America, INC. | $350.59 | 2021-2023 | Xeomin |
| Lilly USA, LLC | $316.48 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $210.41 | 2021-2025 | |
| Dermavant Sciences, INC. | $147.31 | 2024 | Vtama |
| Mimedx Group, INC. | $112.30 | 2024-2025 | |
| Almirall LLC | $108.79 | 2019-2024 | Klisyri, Seysara |
| Abbvie INC. | $108.51 | 2021-2024 | |
| Journey Medical Corporation | $102.05 | 2019-2022 | |
| Leo Pharma INC. | $80.21 | 2023-2025 | Anzupgo, Adbry |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $74.63 | 2023-2024 | Otezla |
| Sanofi-Aventis U.S. LLC | $71.64 | 2020-2021 | |
| Galderma Laboratories, L.P. | $70.45 | 2021-2023 | |
| Vyne Pharmaceuticals INC. | $53.00 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $40.62 | 2021-2023 | Libtayo |
| Verrica Pharmaceuticals INC. | $27.88 | 2024 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $23.04 | 2024 | Cabtreo, Jublia |
| Allergan, INC. | $22.17 | 2022 | |
| Sandoz INC. | $20.60 | 2020 | |
| Apyx Medical Corporation | $18.84 | 2019 | |
| Biofrontera INC. | $17.81 | 2019 | |
| Prugen, INC. Pharmaceuticals | $15.01 | 2020 | |
| Dermira, INC. | $14.46 | 2021 | |
| Mylan Pharmaceuticals INC. | $10.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.